Best Practices in NSCLC Molecular Testing, Part II


For High-Definition, Click

David Gandara, MD, begins the conversation by asking a question about the timing of treatment in relation to diagnosis.

Alan B. Sandler, MD, states that while deciding on a treatment early on is important, he also sticks to the idea to refrain from ordering a test until he plans on doing something with the information. Depending on the likelihood of positive results, Sandler can adjust the plan.

In some cases, Corey J. Langer, MD, says, such as in node positive patients who have undergone definitive resection and have plans for resection, exceptions can be made. Certain tests can take multiple weeks to deliver results.

Gandara concludes the conversation by mentioning a new program led by Alliance and the National Cancer Institute where 8,000 early stage patients will undergo molecular testing for trials and their information will be available for later use.

View Part I of the discussion

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic
Federico Cappuzzo, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Edgardo S. Santos Castillero, MD, FACP
Joshua K. Sabari, MD
Coral Olazagasti, MD